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meant these patients had greatest propensity for quality-of-life improvements and
QALY gains, resulting in the public subsidy recommendation in this patient sub-
group by the PBAC in Australia. CONCLUSIONS: Patients using MOCS with a base-
line ACQ-5 2.0 or AQLQ 5.0 are those in whom OM shows optimal cost-effec-
tiveness in the Australian healthcare environment.
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OBJECTIVES: To assess the cost-effectiveness of indacaterol in comparison to
tiotropium and formoterol from Brazilian public healthcare system perspective.
METHODS: A Markov model was designed to project costs and outcomes associ-
ated with disease progression of patients with COPD over 3-years time horizon. The
model health states are divided by severity of COPD (mild, moderate, severe and
very severe) with each of these states divided into three states: no exacerbation,
non-severe and severe exacerbations. The target population consists of patients
with moderate or severe COPD, and the health states for mild and very severe COPD
are included to account for those who improve in first cycle to the mild state and
those who progress to very severe state over time. Efficacy data and exacerbation
rates were obtained from the pivotal trials. Mortality data for COPD-specific states
are based on study by Rutten-van Mölken et al. COPD related medical resource
utilization patterns were assessed through clinical experts’ panel. Unit costs were
extracted from Brazilian official lists. Outcomes are expressed as life years gained
(LYG). One-way sensitivity analysis was performed. Annual discount rate of 5% was
applied both to costs and outcomes. RESULTS: Base case analysis estimated incre-
mental LYG for indacaterol of 0.010 vs. formoterol and 0.006 vs. tiotropium. Inda-
caterol was cost-saving as compared to tiotropium (incremental cost of -2,667BRL).
Comparing to formoterol, the projected ICER was 25,458BRL per LYG. The variables
that most influenced the results were time horizon, mortality rates and baseline
population.CONCLUSIONS: Indacaterol is a valuable alternative for COPD patients,
being a cost-saving treatment vs. tiotropium with incremental clinical benefits and
lower costs. Versus formoterol, indacaterol has incremental benefit, at a reason-
able incremental cost.
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OBJECTIVES: The objective of this analysis was to compare results of two cost-
effectiveness analyses for omalizumab added to standard therapy in severe allergic
asthma patients using an RCT (INNOVATE) compared to a real-world, prospective
observational study (EXPERIENCE). METHODS: A Markov model was developed to
examine the cost-effectiveness of add-on omalizumab versus standard care from
the perspective of the Dutch health care system over a patient’s lifetime. Efficacy
data for clinically significant (CS) exacerbations and resource use (hospital admis-
sions, unscheduled physician visits and emergency visits) were derived from IN-
NOVATE or Dutch patients enrolled in EXPERIENCE. Data from each were projected
to lifetime with discounted future costs (4%) and outcomes (1.5%). RESULTS: For
the EXPERIENCE study, the modelled direct medical costs for patients on standard
therapy were €77,615, of which 75% was for exacerbation control versus €133,475
for standard therapy  omalizumab, of which 38% was for exacerbation control.
Patients on omalizumab had more QALYs than those on standard therapy alone,
12.05 versus 10.47. The resulting ICER was €35,257/QALY for the EXPERIENCE study.
The INNOVATE costs were lower in both treatment arms: €22,499 for standard
therapy and €58,666 for standard therapy  omalizumab. Costs were lower due to
lower rate of CS exacerbations in the RCT where patients had been under best
possible control at trial entry. QALYs were similar to the EXPERIENCE study 12.05
and 10.91, respectively; resulting in €31,802/QALY. CONCLUSIONS: Decision-mak-
ers are often presented with cost-effectiveness evidence from RCTs although they
prefer to base decisions on real-world data are preferred. This study is one the first
to include both in a re-evaluation dossier. It showed differences in patient charac-
teristics (exacerbation rates and resource use) between the RCT and observational
study. However it confirmed the value of omalizumab with similar ICERs, indicat-
ing that omalizumab is cost effective in both settings.
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OBJECTIVES: To evaluate the cost-effectiveness of varenicline compared to bupro-
pion and nicotine-replacement therapy (NRT) from a third-party payer (Social In-
surance Fund) perspective in Greece. METHODS: The Benefits of Smoking Cessa-
tion on Outcomes (BENESCO) Markov model was applied to calculate the long-term
health and economic benefits of smoking cessation, simulating the incidence and
outcomes of smoking-related morbidities to a hypothetical cohort of patients (age-
and gender-representative of the Greek population) making a single quit attempt.
Demographic, epidemiological, treatment efficacy and economic inputs for the
modelled cohort were obtained from the literature and publicly available data from
public healthcare databases. The model calculated costs and outcomes for a life-
time perspective, discounted at a 3% discount rate and reported in year 2011 fees
and prices. Extensive probabilistic sensitivity analysis was performed to test the
robustness of the results. RESULTS: The cohort consisted of 819,709 current smok-
ers making a quit attempt. The respective 1year continuous abstinence rates were
22.5%, 15.5% and 15.4% for quitters under varenicline, NRT and bupropion. For a
lifetime horizon, varenicline prevented in total 7652 and 7609 additional cases of
smoking-related disease (coronary heart disease, stroke, lung cancer, chronic ob-
structive pulmonary disease) versus NRT and bupropion, respectively. Moreover,
varenicline led to a gain of 21,219 QALYs (16,955 life years) and 21,099 QALYs (16,859
life years) for the cohort, compared to NRT and bupropion. Taking direct costs into
account, varenicline produced cost-savings against both comparators for the life-
time as well as for shorter (20year) timeframes of analysis. The probabilistic sen-
sitivity analysis corroborated the study outcomes. CONCLUSIONS: Taking into ac-
count the Social Security perspective in Greece, varenicline was a dominant
smoking cessation strategy compared to NRT and bupropion, reducing both treat-
ment costs and smoking-related morbidity.
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OBJECTIVES: To estimate the cost-effectiveness of roflumilast (Daxas®) versus the
most prescribed drug combination in Spain in the treatment of adult patients with
severe chronic obstructive pulmonary disease (COPD) with a history of frequent
exacerbations. METHODS: A Markov model was constructed to estimate the life
time cost-effectiveness of roflumilast plus a long acting muscarinic antagonist
(roflumilast  LAMA) versus the combination of LAMA with a long-acting beta
agonist plus and an inhaled corticosteroid (LAMALABA/ICS). Outcomes were ex-
pressed as the incremental cost per exacerbation avoided from the Spanish Na-
tional Health System perspective using a life-time horizon (30 years). Other health
outcomes in the model include quality-adjusted life year (QALY) gained and life
years (LY) gained. The key inputs to the model are based on roflumilast pivotal
clinical trials and published epidemiological and population data. Uncertainty in
the model’s parameters was examined by sensitivity analysis. RESULTS: The re-
sults of the economic analysis have demonstrated that over the lifetime of the
treatment of patients with severe COPD and associated chronic bronchitis with a
history of frequent exacerbations, the roflumilast LAMA strategy will cost 3468 €
less than using LAMA  LABA/ICS. Over a lifetime a patient treated with a roflu-
milast LAMA is estimated to have 1.23 exacerbations less and 0.129 more QALYs
that a patient treated with LAMA LABA/ICS. Therefore, the roflumilast treatment
arm appears to be the dominating option. The sensitivity analyses showed that the
variable that has the most impact on the ICER results is the relative risk of
exacerbations. CONCLUSIONS: Roflumilast  LAMA offers a cost-effective option
for the maintenance treatment of severe COPD associated with chronic bronchitis
in patients with a history of frequent exacerbations compared with LAMA LABA/
ICS.
PRS35
ECONOMIC EVALUATION OF INDACATEROL VERSUS TIOTROPIUM OR
FORMOTEROL FOR PATIENTS WITH MODERATE TO SEVERE COPD IN GREECE
Geitona M1, Hatzikou M2, Bania E2
1University of Peloponnese, Athens, Greece, 2Novartis Hellas, Metamorfosis, Greece
OBJECTIVES: Evaluate the cost-effectiveness of indacaterol (Onbrez Breezhaler,
150g & 300g) against tiotropium (Spiriva, 18g) or formoterol (Foradil, 12g twice
daily) respectively. METHODS: A Markov model was developed describing each
COPD disease severity stage based on pre-bronchodilator FEV1 measurements re-
ported in the indacaterol clinical trials (INVOLVE & INHANCE). The outcomes as-
sessment criteria were Quality-Adjusted Life-Years (QALYs), Life Years Gained
(LYG) and exacerbation rates. A 3-year time horizon was used for the cost-utility
analysis (CUA) and a lifetime (25 year) time horizon was used for the cost-effec-
tiveness analysis (CEA). Discount rates of 3.5% were set for both costs and out-
comes and univariate sensitivity analyses were conducted. Resource utilization
was based on Greek published data and relevant costs on official NHS prices.
RESULTS: The mean number of QALYs per patient in the three-year CUA was 2.152
in the indacaterol 150g arm and 2.144 in the tiotropium arm, resulting in 0.0078
QALYs in favor of indacaterol; the total costs per patient were €9,717 in the inda-
caterol arm and €9,853 in the tiotropium arm, resulting in €136 savings in favor of
indacaterol, gaining the dominant position (lower total costs, better outcomes).
The CEA over the lifetime is similarly dominant with 10.213 LYG for indacaterol and
10.119 LYG for tiotropium and a lower cost per patient for indacaterol. The CUA
comparing indacaterol 300g and formoterol also resulted in indacaterol dominat-
ing formoterol with an incremental QALY of 0.017 (2.149 and 2.132 respectively) and
a cost saving of €48.23 compared to formoterol over 3 years. Similarly, indacaterol
dominates the CEA over a life time. Regarding exacerbation rates, although very
similar outcomes appeared among treatments, COPD treatment was less costly
with indacaterol against all other comparators. CONCLUSIONS: For patients with
moderate to severe COPD, indacaterol represents a cost-effective treatment and is
potentially cost saving for the Greek NHS.
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